CLINICAL PRESENTATION AND BACTERIOLOGICAL PROFILE OF ICU ADMITTED PATIENTS WITH VENTILATOR ASSOCIATED PNEUMONIA IN KHYBER TEACHING HOSPITAL PESHAWAR
DOI:
https://doi.org/10.33279/jkcd.v15i01.653Keywords:
Bacteria, Pneumonia, ICU, PeshawarAbstract
Objectives: To determine bacteriological profile of ICU admitted patients with ventilator associated pneumonia.
Materials and Methods: A descriptive cross-sectional study was conducted from July 2018 to April 2020 at department of Medical ICU. A total of 172 patients were observed for clinical presentation and bacteriological profile in ventilator associated pneumonia. Data were presented in form of frequency and percentages.The p-value less than 0.05 were considered as statistically significant.
Results: Out of 172 patients, 24 (13.71%) and 18 (10.2%) were having Diabetes Mellitus (DM) and Hypertension (HTN), respectively. Patients who received mechanical ventilation for 0-5 days had a relatively low recovery rate of 8.8%, with the majority (91%) unfortunately expiring. In the 6–10-day category, there was a slightly higher recovery rate of 14.8%, but still, the majority (85%) of patients did not survive. Patients with >16 days of ventilation, show higher recovery rate (35.2%). The highest number of bacteria was isolated from the patients with 0-5 day’s ventilation while there was a lowest growth of bacteria in 6-10 days ventilated patients. In antibiotics susceptibility, there are variations in antibiotic eff ectiveness across different bacterial strains and antibiotics. Fosfomycin and Tigecycline show highest eff ect against all bacteria except Acinobacter baumannii while Colistin was effective against all the bacteria except Pseudomonas.
Conclusion: Patients on mechanical ventilation had lower chances of recovery in the early days, but those who were ventilated longer showed better outcomes. Diabetes Mellitus and Hypertension were common comorbidities. Bacterial growth was highest in the early days of ventilation. Antibiotics like Fosfomycin and Tigecycline show highest eff ect against all bacteria except Acinobacter baumannii whereas Colistin was also eff ective against all, except for Pseudomonas.
References
Zambare KK, Thalkari AB. Overview on pathophysiology of pneumonia. Asian Journal of Pharmaceutical Research. 2019;9(3):177-80.
Akhtar P, Ahmad I, Jameela A, Nazli S, Ahmed K. Sign, Symptom, Prevention and Management of Pneumonia and Herbal Drugs for its Treatment. A Review Article. JETIR. 2020; 7(11): 356-368.
Chiner-Vives E, Cordovilla-Perez R, De la Rosa-Carrillo D, Garcia-Clemente M, Izquierdo-Alonso JL, Otero-Candelera R, etal. Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. Arch Bronconeumol. 2022 Apr 1;58:39-50.
Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS/ ESICM/ ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017;50(3):1700582.
Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020 Jun 1;49(3):717-726.
Halat DH, Moubareck CA. Hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19. F1000Res. 2024 Mar 25;12:92.
Candel FJ, Salavert M, Estella A, Ferrer M, Ferrer R, Gamazo JJ, et al. Ten Issues to Update in Nosocomial or Hospital-Acquired Pneumonia: An Expert Review. J Clin Med. 2023; 12(20):6526
Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens. 2021; 10(10):1310.
Alshammari MK, Alotaibi MA, AlOtaibi AS, Alosaime HT, Aljuaid MA, Alshehri BM, et al. Prevalence and Etiology of Community- and Hospital-Acquired Pneumonia in Saudi Arabia and Their Antimicrobial Susceptibility Patterns: A Systematic Review. Medicina (Kaunas). 2023 Apr 13;59(4):760.
Bankar NJ, Ugemuge S, Ambad RS, Hawale DV, Timilsina DR. Implementation of Antimicrobial Stewardship in the Healthcare Setting. Cureus. 2022 Jul 8;14(7):e26664.
Howroyd F, Chacko C, MacDuff A, Gautam N, Pouchet B, Tunnicliff e B, et al. Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges. Nature Communications. 2024 Jul 31;15(1):6447.
Singh C, Abdullah R. Impact of Ventilator-Associated Pneumonia Preventative Measures and Ventilator Bundle Care in a Tertiary Care Hospital's Adult Intensive Care Unit. Cureus. 2024 May 8;16(5):e59877.
Chaïbi K, Péan de Ponfi lly G, Dortet L, Zahar JR, Pilmis B. Empiric Treatment in HAP/VAP:“Don’t You Want to Take a Leap of Faith?”. Antibiotics. 2022 Mar 8;11(3):359.
Pittaway H, Grudzinska F, Livesey A, Quarton S, Adiga A, Dosanjh D, et al. Management of Non-Ventilated hospital acquired pneumonia. Clinical Infection in Practice. 2024 Feb 11; 21 (2020):100350.
Ntusi N, Aubin L, Oliver S, Whitelaw A, Mendelson M. Guideline for the optimal use of blood cultures. S Afr Med J. 2010 Dec 1;100(12):839-43.
Beal SG, Ciurca J, Smith G, John J, Lee F, Doern CD, et al. Evaluation of the nanosphere verigene gram-positive blood culture assay with the VersaTREK blood culture system and assessment of possible impact on selected patients. J Clin Microbiol. 2013 Dec;51(12):3988-92.
Jaung MS, Willis R, Sharma P, Aebischer Perone S, Frederiksen S, Truppa C, et al. Models of care for patients with hypertension and diabetes in humanitarian crises: a systematic review. Health Policy Plan. 2021 May 17;36(4):509-532.
Wearne N, Davidson B, Blockman M, Jones J, Ross IL, Dave JA. Management of Type 2 Diabetes Mellitus and Kidney Failure in People with HIV-Infection in Africa: Current Status and a Call to Action. HIV AIDS (Auckl). 2023 Sep 6;15:519-535.
McPhail SM. Multimorbidity in chronic disease: impact on health care resources and costs. Risk Manag Healthc Policy. 2016 Jul 5;9:143-56.
Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Kadiane-Oussou NJ, et al. Impact of tocilizumab on mortality and/ or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020 Oct;99:491-495.
Altamimi I, Almazyed A, Alshammary S, Altamimi A, Alhumimidi A, Alnutaifi R, et al. Bacterial Pathogens and Antimicrobial Susceptibility Patterns of Urinary Tract Infections in Children during COVID-19 2019-2020: A Large Tertiary Care Center in Saudi Arabia. Children (Basel). 2023 May 30;10(6):971.
Montero MM, Horcajada JP. Multidrug-resistant Pseudomonas aeruginosa: A pathogen with challenging clinical management. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Oct;41(8):451-453.
Elfadadny A, Ragab RF, AlHarbi M, Badshah F, Ibáñez-Arancibia E, Farag A, et al. Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies. Front Microbiol. 2024 Apr 5;15:1374466.
Sun W, Weingarten RA, Xu M, Southall N, Dai S, Shinn P, et al. Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria. Emerg Microbes Infect. 2016 Nov 9;5(11):e116.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mohammad Haroon
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
